Nuwellis (NASDAQ:NUWE) vs. Ambu A/S (OTCMKTS:AMBBY) Head to Head Survey

Ambu A/S (OTCMKTS:AMBBY) and Nuwellis (NASDAQ:NUWE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Volatility & Risk

Ambu A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ambu A/S and Nuwellis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ambu A/S	$894.37 million	2.69	$90.19 million	$0.30	34.08
Nuwellis	$8.27 million	0.33	-$17.52 million	($132.59)	-0.01

Ambu A/S has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ambu A/S and Nuwellis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ambu A/S	8.18%	8.49%	6.75%
Nuwellis	-123.38%	-623.14%	-147.34%

Analyst Ratings

This is a summary of recent recommendations and price targets for Ambu A/S and Nuwellis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ambu A/S	0	1	0	0	2.00
Nuwellis	1	0	0	0	1.00

Insider and Institutional Ownership

3.1% of Nuwellis shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Ambu A/S beats Nuwellis on 10 of the 12 factors compared between the two stocks.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.